SCHEMBL30983378

SCHEMBL30983378

CC1(Oc2ncnc3c2nc(-c2ccc(OCCN4CCNCC4)cc2Cl)n3Cc2cccc(Cl)c2)CC1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ HTR6 P50406 9/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ PDE2A O00408 1/20 0.39
▸ DRD2 P14416 3/20 0.39
▸ HTR1A P08908 2/20 0.39
▸ HTR2A P28223 2/20 0.39
▸ HTR7 P34969 2/20 0.39
▸ CNR1 P21554 1/20 0.38
▸ LTA4H P09960 1/20 0.36
▸ HTR2C P28335 1/20 0.36
▸ LMNA P02545 1/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ KCNH2 Q12809 1/20 0.35
▸ MCHR1 Q99705 1/20 0.35
▸ HRH4 Q9H3N8 1/20 0.35
▸ TLR7 Q9NYK1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30983795 0.94 PDE2A (0.42) HTR6KDM4EALDH1A1PDE2ADRD2
SCHEMBL30983428 0.93 KMT2A (0.43) KDM4EALDH1A1DRD2CNR1LTA4H
SCHEMBL30984054 0.91 PDE2A (0.42) HTR6KDM4EALDH1A1PDE2ADRD2
SCHEMBL30984056 0.91 PDE2A (0.42) HTR6KDM4EALDH1A1PDE2ADRD2
SCHEMBL31269141 0.91 PDE2A (0.37) KDM4EALDH1A1PDE2ADRD2HRH4
SCHEMBL30983420 0.91 HRH4 (0.41) HTR6ALDH1A1PDE2ADRD2HTR1A
SCHEMBL31269041 0.90 PDE2A (0.38) HTR6KDM4EALDH1A1PDE2ADRD2
SCHEMBL31268993 0.90 PDE2A (0.38) HTR6KDM4EALDH1A1PDE2ADRD2
SCHEMBL30983545 0.90 KDM4E (0.39) HTR6KDM4EALDH1A1PDE2ADRD2
SCHEMBL30984048 0.89 PDE2A (0.38) HTR6KDM4EALDH1A1PDE2ADRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4630410-A1 POLQ INHIBITORS Astrazeneca AB (SE) 2025-10-15 — — EP claimed
WO-2024121753-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2024-06-13 — — WO claimed
EP-4689155-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS Astrazeneca AB (SE) 2026-02-11 — — EP disclosed
EP-4630410-A1 POLQ INHIBITORS Astrazeneca AB (SE) 2025-10-15 — — EP disclosed
US-12414954-B2 POLQ inhibitors ASTRAZENECA AB (SE) 2025-09-16 — — US disclosed
US-20250195530-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2025-06-19 — — US disclosed
US-20240366615-A1 POLQ INHIBITORS ASTRAZENECA UK LIMITED (GB) 2024-11-07 — — US disclosed
WO-2024201368-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS ASTRAZENECA AB (SE) 2024-10-03 — — WO disclosed
WO-2024121753-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2024-06-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240366615-A1 POLQ INHIBITORS POLQ, POLG, POLB HTR6 4806/4885KDM4E 2215/4885ALDH1A1 3824/4885
US-12414954-B2 POLQ inhibitors POLQ, POLG, POLB HTR6 4806/4885KDM4E 2215/4885ALDH1A1 3824/4885
US-20250195530-A1 POLQ INHIBITORS POLQ, POLG, POLB HTR6 4806/4885KDM4E 2215/4885ALDH1A1 3824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback